Lapatinib: A review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer

Drugs

Volumn 69, Issue 15, 2009, Pages 2125-2148

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; MONOCLONAL ANTIBODY; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TAXOID; TRASTUZUMAB;

BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW; TUMOR CELL LINE;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TAXOIDS;

EID: 74049139094     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203240-000000000-00000     Document Type: Review

References (104)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar; 55 (2): 74-108
2. Bartsch R, Wenzel C, Zielinski CC, et al. HER-2-positive breast cancer: hope beyond trastuzumab. Biodrugs 2007; 21 (2): 69-77
3. McArthur H. An overview of HER-targeted therapy with lapatinib in breast cancer. Adv Ther 2009 Mar; 26 (3): 263-71
4. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12 (7): 756-65
5. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8 (6): 215
6. Spector N, Xia W, El-Hariry I, et al. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007; 9: 205-13
7. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006 Dec 28; 355 (26): 2733-43
8. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009 Apr; 14 (4): 320-68
9. Lin N, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 2004 Jul 29; 6 (5): 204-10
10. Dhillon S, Wagstaff AJ. Lapatinib. Drugs 2007; 67 (14): 2101-8; discussion 2109-10
11. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer: monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009 Apr; 35 (2): 121-36
12. Bilancia D, Rosati G, Dinota A, et al. Lapatinib in breast cancer. Ann Oncol 2007 Jun; 18 Suppl. 6: vi26-30
13. IwataH, ToiM, Fujiwara Y, et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer [abstract no. 1091]. Breast Cancer Res Treat 2006 Dec; 100 Suppl. 1: S68
14. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008 Jun; 19 (6): 1068-74
15. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on firstor second-line trastuzumab-containing regimens. Ann Oncol 2009 Jun; 20 (6): 1026-31
16. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008 Mar 1; 26 (7): 1066-72
17. Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009 Jun; 10 (6): 581-8
18. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006 Nov; 11 (10): 1047-57
19. Tyverb® 250mg film-coated tablets. Summary of product characteristics. Uxbridge: GlaxoSmithKline Group of Companies, 2008 Jun
20. Halterman PA. Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Pharmacotherapy 2008 Oct; 28 (10): 1255-66
21. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 Dec; 1: 85-94
22. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004 Sep 15; 64 (18): 6652-9
23. Xia W, Mullin RJ, Keith BR, et al. Antitumour activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-63
24. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007 Feb; 7 (2): 257-68
25. Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today 2006 Jul; 42 (7): 441-53
26. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006 Feb 1; 66 (3): 1630-9
27. Hegde PS, Rusnak D, Bertiaux M, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007; 6 (5): 1629-40
28. Zhang D, Pal A, Bornmann WG, et al. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008 Jul; 7 (7): 1846-50
29. Spector NL, Xia W, Burris 3rd H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005 Apr 10; 23 (11): 2502-12
30. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008 Dec; 112 (3): 533-43
31. Press MF, Finn RS, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008 Dec 1; 14 (23): 7861-70
32. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci 2006; 103 (20): 7795-800
33. Xia W, Bisi J, Strum J, et al. Regulationofsurvivin byErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 2006 Feb 1; 66 (3): 1640-7
34. Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005 Sep 15; 24 (41): 6213-21
35. GlaxoSmithKline. Tykerb (lapatinib) tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmthKline, 2008 Jul
36. Chu QS, Schwartz G, de Bono J, et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol 2007 Aug 20; 25 (24): 3753-8
37. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009 Feb 12; 28 (6): 803-14
38. Nahta R, Yuan LX, Du Y, et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007 Feb; 6 (2): 667-74
39. Nahta R, Yuan LXH, Zhang B, et al. Insulin-like growth factor-1 receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005 Dec 1; 65 (23): 11118-28
40. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007 Apr 18; 99 (8): 628-38
41. Tomasello G, de Azambuja E, Dinh P, et al. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008 Dec; 8 (12): 1883-90
42. Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004 Jan 22; 23 (3): 646-53
43. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-ampli-fied locally advanced or metastatic breast cancer. J Clin Oncol 2008 Jun 20; 26 (18): 2999-3005
44. Guix M, Aura CM, Jimenez J, et al. Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2 [abstract no. 708]. 31st Annual San Antonio Breast Cancer Symposium; 2008 Dec 10-14; San Antonio (TX)
45. Prudkin L, Aura CM, Jimenez J, et al. Clinical benefit of lapatinib-based therapy in patients with HER2-positive breast tumors expressing p95HER2 [abstract no. 1048]. J Clin Oncol 2009; 27 Suppl.: 15s
46. Xia W, Husain I, Liu L, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007 Feb 1; 67 (3): 1170-5
47. Migliaccio I, Gutierrez MC, Wu MF, et al. PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). Cancer Res 2009; 69 Suppl. 2: 71s
48. Eichhorn PJA, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68 (22): 9221-30
49. Johnston SRD. Integration of endocrine therapy with targeted agents. Breast Cancer Res 2008; 10 Suppl. 4: S20
50. Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine ki-nase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217-33
51. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004; 9 Suppl. 3: 20-6
52. Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with ta-moxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005 Jan 1; 65 (1): 18-25
53. Leary A, Lykkesfeldt A, Martin LA, et al. Enhancing endocrine responsiveness using the dual EGFR/HER2 tyr-osine kinase inhibitor lapatinib in cell models of endocrine resistance [abstract no. 303]. Breast Cancer Res Treat 2006; 100 Suppl. 1: S29
54. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line post-menopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 trial [abstract no. 46]. 31st Annual San Antonio Breast Cancer Symposium; 2008 Dec 10-14; San Antonio (TX)
55. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008 Aug 6; 100 (15): 1092-103
56. Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl] amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009 Feb; 37 (2): 439-42
57. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluoro benzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008; 36 (4): 695-701
58. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008 Apr 20; 26 (12): 1993-9
59. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009 Feb 15; 15 (4): 1452-9
60. Gluck S, Castrellon A. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases. Am J Ther. Epub 2009 May 19
61. Bence AK, Anderson EB, Halepota MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005 Jan; 23 (1 Pt A): 39-49
62. Burris 3rd HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pre-treated patients with metastatic carcinomas. J Clin Oncol 2005 Aug 10; 23 (23): 5305-13
63. Koch K, Lee D, Jones S, et al. Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients [abstract no. 559]. EJC Supplements 2003 Sep 5; 1 (5): S169
64. European Medicines Agency. Assessment report for Tyverb [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tyverb/H-795- en6.pdf [Accessed 2009 Aug 7]
65. Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009 Mar 10; 27 (8): 1191-6
66. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008 Jul 10; 26 (20): 3317-23
67. Chu QS, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 2008 Jul 15; 14 (14): 4484-90
68. LoRusso PM, Jones SF, Koch KM, et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008 Jun 20; 26 (18): 3051-6
69. Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/ fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 2007 Aug 1; 13 (15 Pt 1): 4495-502
70. Midgley RS, Kerr DJ, Flaherty KT, et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 2007 Dec; 18 (12): 2025-9
71. Smith DA, Koch KM, Arya N, et al. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009 Apr; 67 (4): 421-6
72. Cardoso F, Koch KM, Awada A, et al. Pharmacokinetics and tolerability of lapatinib administered once daily in combination with tamoxifen [abstract no. 2073]. 31st Annual San Antonio Breast Cancer Symposium; 2008 Dec 10-14; San Antonio (TX)
73. Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that over-expresses HER-2. Oncologist 2008 Oct; 13 (10): 1114-9
74. Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008 Sep 2; 99 (5): 711-5
75. Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. Epub 2009 Jan 20
76. Sonpavde G. Lapatinib plus capecitabine in breast cancer [5] [letter]. N Engl J Med 2007; 356 (14): 1471
77. Cameron D, Martin A-M, Newstat B, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): updated efficacy and biomarker analyses [abstract no. 1035 plus poster]. 43rd American Society of Clinical Oncology Annual Meeting; 2007 Jun 1-5; Chicago (IL)
78. Crown J, Casey MA, Cameron D, et al. Lapatinib (L) plus capecitabine (C) in HER2+ metastatic breast cancer (MBC): exploratory analyses by prior therapy [abstract P5082]. Joint European Cancer Organisation 15th - European Society for Medical Oncology 34th Multi-disciplinary Congress; 2009 Sep 20-24; Berlin
79. Blackwell KL, Burstein HJ, Storniolo AM, et al. A randomized study of the efficacy and safety of lapatinib in combination with trastuzumab and as monotherapy after progression on trastuzumab in heavily pretreated ERBB2+ metastatic breast cancer [abstract no. 137P]. Ann Oncol 2008 Sep 12; 19 Suppl. 8: viii64
80. Dickler M, Franco S, Stopeck A, et al. Final results from a phase II evaluation of lapatinib and bevacizumab in HER2-overexpressing metastatic breast cancer [abstract no. 3133]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 242s
81. Crown JP, Burris 3rd HA, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapa-tinib. Breast Cancer Res Treat 2008 Nov; 112 (2): 317-25
82. Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with la-patinib. Breast Cancer Res Treat 2009 Apr; 114 (3): 485-93
83. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008 Jun; 83 (6): 679-86
84. Delea T, Tappenden P, Sofrygin O, et al. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who received prior therapy with trastuzumab based on updated survival data from EGF100151 [abstract no. 6559]. 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30-Jun 3; Chicago (IL)
85. Delea T, Sofrygin O, Tappenden P, et al. Cost-effectiveness (CE) analysis of ERBB2-targeted therapies in women with trastuzumab (TZ)-refractory ERBB2+ metastatic breast cancer (MBC) and limited exposure to prior chemotherapy [abstract no. PCN 71]. 14th Annual International Meeting of the International Society for Pharmacoeco-nomics and Outcomes Research (ISPOR); 2009 May 16-20; Orlando (FL)
86. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold: how high should it be? BMJ 2007 Aug 25; 335: 358-9
87. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009 Apr 20; 27 (12): 1999-2006
88. Dickler MN, McArthur HL. The evolving role of lapatinib in the management of women with HER2-positive breast cancer [online]. Available from URL: http://www.ajho.com [Accessed 2009 Jun 17]
89. McArthur H. An overview of HER-targeted therapy with lapatinib in breast cancer. Adv Ther 2009 Mar; 26 (3): 263-71
90. Ito Y, Tokudome N, Sugihara T, et al. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? Breast Cancer 2007; 14 (2): 156-62
91. Stemmler H-J, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008 Jul; 13 (7): 739-50
92. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62 (1): 209-43
93. Petrelli F, Cabiddu M, Cazzaniga ME, et al. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 2008 Apr; 13 (4): 373-81
94. Reid A, Vidal L, Shaw H, et al. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007 Feb; 43 (3): 481-9
95. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997 Jan; 15 (1): 110-5
96. Herceptin: summary of product characteristics. Welwyn Garden City: Roche Products Ltd, 2009 Feb 11
97. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract no. 1015]. J Clin Oncol 2008; 26 (May 20 Suppl.)
98. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, doubleblind, randomized study comparing lapatinib plus pacli-taxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008 Dec 1; 26 (34): 5544-52
99. Tykerb evaluation after chemotherapy (TEACH): lapatinib versus placebo in women with early-stage breast cancer [Clin-icalTrials.gov identifier NCT00374322]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Jun 12]
100. Fumoleau P. Future options in the treatment of ErbB2 (HER2)-positive breast cancer. EJC Supplements 2008 Mar; 6 (5): 25-31
101. ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study: BIG 2-06/NO63D [ClinicalTrials.gov identifier NCT00490139]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Jun 12]
102. Chan S, Burris HA, Lacouture ME, et al. Pooled analysis of skin and diarrhea events in cancer patients treated with lapatinib [abstract no. 2112]. EJC Supplements 2007 Sep 1; 5 (4): 217
103. Popat S. Therapy insight: anthracyclines and trastuzumab - the optimal management of cardiotoxic side effects [online]. Available from URL: http://cme.medscape.com/viewarticle/571829 [Accessed 2009 Jun 22]
104. Martin M, Esteva FJ, Alba E, et al. Minimizing cardio-toxicity while optimizing treatment efficacy with trastu-zumab: review and expert recommendations. Oncologist 2009 Jan; 14 (1): 1-11